Earnings ·
Gain Therapeutics reports Q2 net loss of $0.11 per share as FDA authorizes IND for rexaceract
GANXGain Therapeutics, Inc.
Gain Therapeutics reported a second-quarter 2026 net loss of $0.11 per share, an improvement from the $0.19 loss in the prior-year period. Research and development expenses decreased to $2.1 million, while general and administrative costs rose slightly to $2.5 million. The company holds $13.1 million in cash as of June 30, 2026. Key operational highlights include FDA authorization of an Investigational New Drug application for rexaceract, enabling the start of Phase 2 clinical development expected in Q3 2026. Additionally, Dr. Joanne Taylor was promoted to Chief Scientific Officer and Terenzio Ignoni to Chief Operating Officer. Gain Therapeutics is a clinical-stage biotechnology company focused on discovering and developing allosteric small molecule therapies for neurodegenerative diseases.